{"id":169245,"date":"2023-01-06T15:25:57","date_gmt":"2023-01-06T15:25:57","guid":{"rendered":"https:\/\/precoinnews.com\/?p=169245"},"modified":"2023-01-06T15:25:57","modified_gmt":"2023-01-06T15:25:57","slug":"curevac-rallies-on-positive-data-from-its-covid-19-flu-vaccine-candidates","status":"publish","type":"post","link":"https:\/\/precoinnews.com\/bitcoin\/curevac-rallies-on-positive-data-from-its-covid-19-flu-vaccine-candidates\/","title":{"rendered":"CureVac Rallies On Positive Data From Its COVID-19, Flu Vaccine Candidates"},"content":{"rendered":"
Shares of CureVac N.V. (CVAC) are rising more than 14% Friday morning after the company announced positive preliminary data from the early-stage studies of COVID-19 and Flu vaccine candidates.<\/p>\n
Results from the Phase 1 study showed that the company’s Covid-19 vaccine candidate CV0501, successfully boosted antibody titers against BA.1 and the wild type variants, and was generally well tolerated across all tested dose groups.<\/p>\n
Flu vaccine candidate Flu-SV-mRNA successfully boosted antibody titers against matching flu strain, even at lowest dose, the company said.<\/p>\n
CureVac plans to advance these vaccine candidates to the next stage of study in this year.<\/p>\n
CVAC is at $7.29 currently. It has traded in the range of $5.63-$31.84 in the last 1 year. <\/p>\n